UpToDate
UpToDate خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده: 4

Emetic risk of single, oral antineoplastic agents in adults*

Emetic risk of single, oral antineoplastic agents in adults*
Risk level Agent
Moderate or high (≥30%)
  • Abemaciclib
  • Avapritinib
  • Bosutinib
  • Cabozantinib
  • Ceritinib
  • Crizotinib
  • Cyclophosphamide
  • Enasidenib
  • Fedratinib
  • Hexamethylmelamine
  • Imatinib
  • Lenvatinib
  • Lomustine
  • Midostaurin
  • Niraparib
  • Procarbazine
  • Ribociclib
  • Rucaparib
  • Selinexor
  • TAS-102 (trifluridine-tipiracil)
  • Temozolomide
  • Vinorelbine
Minimal or low (<30%)
  • 6-Thioguanine
  • Acalabrutinib
  • Afatinib
  • Alectinib
  • Alpelisib
  • Axitinib
  • Bexarotene
  • Brigatinib
  • Capecitabine
  • Chlorambucil
  • Cobimetinib
  • Dabrafenib
  • Dacomitinib
  • Dasatinib
  • Duvelisib
  • Encorafenib
  • Entrectinib
  • Erdafitinib
  • Erlotinib
  • Estramustine
  • Etoposide
  • Everolimus
  • Fludarabine
  • Gefitinib
  • Gilteritinib
  • Glasdegib
  • Hydroxyurea
  • Ibrutinib
  • Idelalisib
  • Ivosidenib
  • Ixazomib
  • Lapatinib
  • Larotrectinib
  • Lenalidomide
  • Lorlatinib
  • Melphalan
  • Methotrexate
  • Neratinib
  • Nilotinib
  • Olaparib
  • Osimertinib
  • Palbociclib
  • Panobinostat
  • Pazopanib
  • Pexidartinib
  • Pomalidomide
  • Ponatinib
  • Regorafenib
  • Ruxolitinib
  • Sonidegib
  • Sorafenib
  • Sunitinib
  • Talazoparib
  • Tazemetostat
  • Tegafur-Uracil
  • Thalidomide
  • Topotecan
  • Trametinib
  • Vandetanib
  • Vemurafenib
  • Venetoclax
  • Vismodegib
  • Vorinostat
  • Zanubrutinib
* The classified emetic potential of oral agents is based on a full course of therapy and not a single dose.
Reproduced with permission from Wolters Kluwer Health, Inc.: Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol 2020; 38(24):2782-2797. Copyright © 2020 American Society of Clinical Oncology. https://ascopubs.org/journal/jco.
Graphic 65923 Version 57.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟